Premium
Drug treatment for bronchopulmonary dysplasia in J apan: Questionnaire survey
Author(s) -
Ogawa Ryo,
Mori Rintaro,
Sako Mayumi,
Kageyama Misao,
Tamura Masanori,
Namba Fumihiko
Publication year - 2015
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/ped.12584
Subject(s) - medicine , bronchopulmonary dysplasia , drug , pediatrics , intensive care medicine , pregnancy , pharmacology , gestational age , genetics , biology
Bronchopulmonary dysplasia ( BPD ) is one of the most common complications in premature infants. Although several different drugs have been developed for BPD , there is a wide variation in the choice of drug used among facilities. The aim of this study was to carry out a survey of the current drugs used to treat BPD in J apan. Questionnaires regarding the current use of drugs for BPD were sent to tertiary neonatal units. The response rate was 80% (77/96). Most units used antenatal steroids and oral diuretics for the prevention and treatment of BPD , respectively. Only 4% used caffeine for prevention, whereas 88% used systemic corticosteroids for treatment. Few units used inhaled anticholinergics and i.v. vitamins for the prevention and treatment of BPD , respectively. It was found that the drugs used to treat BPD vary greatly among institutions. Further research is required to develop evidence‐based clinical guidelines for BPD in premature infants.